← Eichor
Study identifier: NCT07077239 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity

Condition: Prostate Cancer (CRPC)  ·  Sponsor: Jonsson Comprehensive Cancer Center

PhaseN/A
Planned participants200
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Single-arm, prospective registry study assessing changes in acute patient-reported urinary (GU) and gastrointestinal (GI) quality of life at the 24-month post-treatment time point following magnetic resonance imaging (MRI)-guided or computed tomography (CT)-guided stereotactic body radiotherapy (SBRT) delivered to the prostate bed +/- pelvic lymph nodes. The decision to offer an adaptive treatment will be at the clinician's discretion.

This description comes directly from the study's public registry record.

Talk to the study team

CHRISTY PALODICHUK  ·  +1 310-794-2971  ·  cpalodichuk@mednet.ucla.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of California at Los AngelesLos Angeles, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07077239